309 results
Page 6 of 16
424B5
q4o4o3zbd3it2 nu
28 May 20
Prospectus supplement for primary offering
12:00pm
6-K
EX-99
qi4fn kby
28 May 20
Current report (foreign)
11:56am
6-K
vdizvltsujfnum8
28 May 20
Current report (foreign)
11:56am
6-K
EX-99
ida0m7pohghfyq ugcia
27 May 20
BioLineRx Announces Publication of Data from Ongoing
7:00am
6-K
EX-99
9r7 rkigns5
26 May 20
BioLineRx Announces $9.0 Million Registered Direct Offering
8:45am
6-K
EX-99
u87p0l0484rhrvptd5m0
20 May 20
BioLineRx Reports First Quarter 2020 Financial Results
7:00am
6-K
EX-99
omfjzppcz3u9f 95u
12 Mar 20
BioLineRx Reports Year-End 2019 Financial Results
7:00am
6-K
EX-99
jr90qovzt0pmetkia4n
27 Feb 20
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination with The COMBAT/KEYNOTE-202 Study
7:00am
6-K
EX-99
a4m6c5
22 Jan 20
BioLineRx Completes Recruitment in Triple Combination
7:00am
6-K
EX-99
y3561m9mdcneuugslqp
14 Jan 20
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of
7:00am
6-K
EX-99
0tsw 07bd
13 Dec 19
BioLineRx Announces Updated Phase 2a Data from Triple
7:00am
6-K
EX-99
q1tjcm96
5 Dec 19
BioLineRx Announces Preliminary Phase 2a Data from Triple
7:00am
6-K
EX-1
562 1asj7w6qv18e
12 Nov 19
Current report (foreign)
6:21am
6-K
EX-99
lz5nb9y0vqri
5 Nov 19
BioLineRx Announces BL-8040 in Combination with KEYTRUDA Shows Clinical Activity in Heavily Pretreated
9:00am
6-K
EX-99
kx88tgw1vcu ospfgm
5 Nov 19
BioLineRx Presents Preclinical Data from Triple Combination
8:00am
6-K
EX-99
nzn fya8dp
25 Sep 19
BioLineRx Announces Dosing of First Patient in Part 2 of
7:00am
6-K
EX-99
4ii7omfxc6ec74
3 Sep 19
BioLineRx Successfully Completes Dose-Escalation Part of
7:00am
6-K
EX-99
kw4e639h2p5
6 Aug 19
BioLineRx Reports Second Quarter 2019 Financial Results
7:11am